摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Methyl-4-(3-methylpyridin-2-YL)piperazine | 1187386-43-1

中文名称
——
中文别名
——
英文名称
1-Methyl-4-(3-methylpyridin-2-YL)piperazine
英文别名
——
1-Methyl-4-(3-methylpyridin-2-YL)piperazine化学式
CAS
1187386-43-1
化学式
C11H17N3
mdl
——
分子量
191.27
InChiKey
ZXHBYUGQYALQNM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    19.4
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
    申请人:SANOFI
    公开号:US20140235616A1
    公开(公告)日:2014-08-21
    The invention relates to compounds corresponding to formula (I), in which R1, R2 and R3 are as defined in Claim 1 , and also to the process for preparing them and to their therapeutic use.
    这项发明涉及与式(I)相对应的化合物,其中R1、R2和R3如权利要求1中所定义,并且还涉及它们的制备方法及其治疗用途。
  • [EN] 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-((HÉTÉRO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DÉCANE
    申请人:GRUENENTHAL GMBH
    公开号:WO2017121648A1
    公开(公告)日:2017-07-20
    The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    这项发明涉及3-((杂-)芳基)-烷基-8-基-2-氧代-1,3-二氮杂-螺[4.5]-癸烷生物,它们的制备以及它们在医学中的应用,特别是在疼痛治疗中的应用。
  • 4-Amino-5-Cyanopyrimidine Derivatives
    申请人:Kato Masaya
    公开号:US20080182854A1
    公开(公告)日:2008-07-31
    The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R 1 , R 2 and R 3 are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating glaucoma, etc., which comprises the compound as an active ingredient.
    本发明提供了式子如下的4-基-5-氰基嘧啶生物:其中R1、R2和R3如本文所定义,或其药学上可接受的盐,具有安全有效的腺苷A2a受体激动活性;同时还提供了一种腺苷A2a受体激动剂、降眼压剂或治疗青光眼等药物,其包含该化合物作为活性成分。
  • 4-Amino-5-cyanopyrimidine derivatives
    申请人:Kato Masaya
    公开号:US20110009620A1
    公开(公告)日:2011-01-13
    The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R 1 , R 2 and R 3 are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating glaucoma, etc., which comprises the compound as an active ingredient.
    本发明提供了式子如下的4-基-5-氰基嘧啶生物:其中R1、R2和R3如本文所定义,或其药学上可接受的盐,具有安全有效的腺苷A2a受体激动活性;同时,本发明还提供了一种腺苷A2a受体激动剂、降低眼内压的药剂或治疗青光眼的药物等,其包含该化合物作为活性成分。
  • IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    申请人:Trabanco-Suarez Andres Avelino
    公开号:US20110009441A1
    公开(公告)日:2011-01-13
    The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    本发明涉及新型化合物,特别是公式(I)中的新型咪唑并[1,2-a]吡啶衍生物。本发明的化合物是代谢型受体亚型2(“mGluR2”)的阳性变构调节剂,可用于治疗或预防与谷酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。特别是,这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的群体。本发明还涉及制备这些化合物和组合物的制药组合物和制备过程,以及将这些化合物用于预防和治疗涉及mGluR2的这些疾病的用途。
查看更多